Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting
March 18 2022 - 7:00AM
Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in
redosable gene therapies for rare diseases, today announced that it
will present late-breaking research at the 2022 American
Academy of Dermatology Annual Meeting, taking place March
25-29 in Boston, Mass.
“We look forward to sharing additional results from Krystal’s
Phase 3 study of the clinical efficacy and safety of beremagene
geperpavec (B-VEC) for the treatment of dystrophic epidermolysis
bullosa (DEB),” said Suma Krishnan, President, Research &
Development, Krystal Biotech, Inc. “This is a terrific opportunity
to raise awareness of DEB among the dermatology community and
convey the need for a therapeutic option that addresses the
underlying genetic cause of the disease.”
Krystal Late-Breaking Presentation
- GEM-3: A phase 3 study of beremagene geperpavec
(B-VEC), an investigational, topical gene therapy, for the
treatment of dystrophic epidermolysis bullosa (DEB)M.
Peter Marinkovich, MD, FAADSession #F045—Late-Breaking Research:
Clinical Studies/PediatricPresentation Date &
Time: Saturday, March 26, 2022, 10:50-11:00 a.m.
EDTLocation: Room 253A at the Boston Convention and Exhibition
Center
About Dystrophic Epidermolysis Bullosa (DEB)DEB
is a rare and severe disease that affects the skin and mucosal
tissues. It is caused by one or more mutations in a gene called
COL7A1, which is responsible for the production of the protein type
VII collagen (COL7) that forms anchoring fibrils that bind the
dermis (inner layer of the skin) to the epidermis (outer layer of
the skin). The lack of functional anchoring fibrils in DEB patients
leads to extremely fragile skin that blisters and tears from minor
friction or trauma. DEB patients suffer from open wounds, which
leads to skin infections, fibrosis which can cause fusion of
fingers and toes, and ultimately an increased risk of developing an
aggressive form of squamous cell carcinoma which, in severe cases,
can be fatal.
About B-VECB-VEC is an investigational
non-invasive, topical, redosable gene therapy designed to deliver
two copies of the COL7A1 gene when applied directly to
DEB wounds. B-VEC was designed to treat DEB at the molecular level
by providing the patient’s skin cells the template to make normal
COL7 protein, thereby addressing the fundamental disease-causing
mechanism.
The U.S. Food and Drug Administration (FDA) and the European
Medicines Agency (EMA) have each granted B-VEC an orphan drug
designation for the treatment of DEB. The FDA has also granted
B-VEC fast track designation and rare pediatric designation
for the treatment of DEB. In addition, in 2019, the FDA granted
Regenerative Medicine Advanced Therapy (“RMAT”) to B-VEC for the
treatment of DEB and the EMA granted PRIority MEdicines ("PRIME")
eligibility for B-VEC to treat DEB.
About Krystal BiotechKrystal Biotech, Inc.
(NASDAQ:KRYS) is a pivotal-stage gene therapy company leveraging
its proprietary, redosable gene therapy platform and in-house
manufacturing capabilities to potentially bring life-changing
treatment options to patients with serious diseases, including rare
diseases in skin, lung, and other areas. For more information,
please visit http://www.krystalbio.com and follow
@KrystalBiotech on LinkedIn and Twitter.
CONTACTS:
Investor ContactWhitney IjemKrystal
Biotechwijem@krystalbio.com
Media ContactTiffany HamiltonKrystal
Biotechthamilton@krystalbio.com
Source: Krystal Biotech, Inc.
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Aug 2023 to Aug 2024